Drug Profile
Research programme: cancer therapeutics - Abbvie/University of Chicago
Latest Information Update: 20 Nov 2021
Price :
$50
*
At a glance
- Originator AbbVie; University of Chicago
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer